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Summary
Alagille syndrome (AGS) is a dominantly inherited dis-
order characterized by liver disease in combination with
heart, skeletal, ocular, facial, renal, and pancreatic ab-
normalities. We have recently demonstrated that Jag-
ged1 (JAG1) is the AGS gene. JAG1 encodes a ligand in
the Notch intercellular signaling pathway. AGS is the
first developmental disorder to be associated with this
pathway and the first human disorder caused by a Notch
ligand. We have screened 54 AGS probands and family
members to determine the frequency of mutations in
JAG1. Three patients (6%) had deletions of the entire
gene. Of the remaining 51 patients, 35 (69%) had mu-
tations within JAG1, identified by SSCP analysis. Of the
35 identified intragenic mutations, all were unique, with
the exceptions of a 5-bp deletion in exon 16, seen in
two unrelated patients, and a C insertion at base 1618
in exon 9, also seen in two unrelated patients. The 35
intragenic mutations included 9 nonsense mutations
(26%); 2 missense mutations (6%); 11 small deletions
(31%), 8 small insertions (23%), and 1 complex rear-
rangement (3%), all leading to frameshifts; and 4 splice-
site mutations (11%). The mutations are spread across
the coding sequence of the gene within the evolutionarily
conserved motifs of the JAG1 protein. There is no phe-
notypic difference between patients with deletions of the
entire JAG1 gene and those with intragenic mutations,
which suggests that one mechanism involved in AGS is
haploinsufficiency. The two missense mutations occur at
the same amino acid residue. The mechanism by which
these missense mutations lead to the disease is not yet
understood; however, they suggest that mechanisms
other than haploinsufficiency may result in the AGS
phenotype.
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Introduction
Alagille syndrome (AGS [MIM 118450]), also known
as arteriohepatic dysplasia, is a multisystem develop-
mental disorder demonstrating autosomal dominant in-
heritance (Alagille et al. 1975; Alagille et al. 1987;
Krantz et al. 1997a). It is one of the most common
genetic causes of chronic liver disease in childhood, with
a minimal estimated frequency of 1/70,000 live births
(Danks et al. 1977). Affected individuals display ab-
normalities of the liver, heart, eyes, skeletal system, facial
features, kidneys, and pancreas, with variable expres-
sion. The criteria for diagnosis, as outlined by Alagille
et al. (1987), include the histologic finding of bile duct
paucity on liver biopsy, in association with three of five
major clinical findings. These major diagnostic criteria
include cholestasis, heart defects (most commonly, in-
volvement of the pulmonary artery and its branches),
posterior embryotoxon (a defect of the anterior chamber
of the eye), vertebral abnormalities (classically, butterfly
vertebrae), and characteristic facial features (a high,
broad forehead; widely spaced, deep-set eyes; and a
prominent, pointed chin, all of which give the face a
“triangular” appearance). Although these criteria are re-
quired to classify an individual as having AGS, it has
long been recognized that family members of AGS pa-
tients may have isolated individual features and that they
most likely represent more mildly expressed forms (mi-
croforms) of the same disorder (Shulman et al. 1984;
Dhorne-Pollet et al. 1994; Elmslie et al. 1995; Krantz et
al. 1997a).
Recently, the human Jagged1 gene (JAG1) on chro-
mosome 20p12 was identified as the AGS disease gene
(Li et al. 1997; Oda et al. 1997). JAG1 encodes a ligand
in the Notch signaling pathway. This pathway has been
extensively studied in Drosophila and Caenorhabditis
elegans and has been shown to be of importance in cell-
fate determination (Kopan and Weintraub 1993; Arta-
vanis-Tsakonas et al. 1995; Robey et al. 1996). The
JAG1 protein is ∼1,220 amino acids in length and is
encoded by a gene that spans 36 kb and is composed
of 26 exons, encoding a 5.5-kb message (Li et al. 1997).
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Figure 1 Structure and evolutionary conservation of the JAG1 protein. Conserved regions include the signal peptide (SP), the delta-serrate-
lin12–like region (DSL), EGF-like repeats, the CR region, and the transmembrane (TM) domain. The amino acid (aa) residues and cDNA base
pairs correlating to the regions in the human protein and cDNA are indicated above the protein diagrams. Homology to the human protein is
indicated on the right.
The JAG1 protein has several domains that show high
interspecies conservation (Lindsell et al. 1995). These
include the DSL domain (an acronym for conserved
regions seen in the Drosophila delta, serrate, and C.
elegans lag 2 genes; Lindsell et al. 1995), the epidermal
growth factor (EGF)–like repeats, and the cysteine-rich
(CR) region (fig. 1). These regions are thought to play
critical roles in ligand-receptor interactions (Muskavitch
1994). Initial studies in multiple families showed that
mutations in this gene segregated with the disease phe-
notype (Li et al. 1997; Oda et al. 1997). All mutations
identified at that time were unique and were predicted
to lead to a truncated protein product that would be
missing its transmembrane domain and would be pre-
sumed to be nonfunctional. The phenotypes of patients
with mutations in JAG1 were indistinguishable from
those of patients with deletions of chromosome 20p12
that encompassed the entire JAG1 gene. These findings
led to the proposal of haploinsufficiency as a mechanism
leading to the disease phenotype.
This study describes the screening of a cohort of AGS
patients and their families, performed to identify the
spectrum of mutations in JAG1 in this population and
to determine whether any correlations between genotype
and phenotype could be established.
Material and Methods
Patients
Fifty-four unrelated patients meeting the diagnostic
criteria for AGS (Alagille et al. 1987) and their family
members were included in the study. Forty-five of the
patients studied here were previously investigated by mi-
crosatellite analysis and FISH for deletions of 20p12
(Krantz et al. 1997b). All patients were referred from
within the United States, with the exception of patient
65, who was from Guatemala. The ethnic backgrounds
of the patients were as follows: Caucasian, 33/54 (61%);
African American, 12/54 (22%); Hispanic, 6/54 (11%);
and Asian, 3/54 (6%). Informed consent was obtained
from all individuals in the study. Lymphoblastoid cell
lines were established and DNA prepared by use of stan-
dard procedures.
FISH
FISH was performed as described elsewhere (Krantz
et al. 1997b), with YACs 940d11 and 881h2.
Microsatellite Analysis
Microsatellite markers from across the previously de-
fined AGS critical region (Krantz et al. 1997b), within
which JAG1 is localized, were used to identify those
patients with deletions encompassing this gene.
SSCP Analysis
SSCP was carried out as described elsewhere (Li et al.
1997). All 26 exons were screened on all probands.
Larger exons (exons 2, 4, 25, and 26) were subdivided
to allow for optimal shift detection on electrophoresis.
All relevant and available family members of probands
with detectable shifts were also analyzed for the specific
exons involved. Primers and PCR conditions are listed
in table 1.
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Table 1
Primers and PCR Conditions Used for SSCP Analysis of the JAG1 Gene
Exon
Sense
(5′–3′)
Antisense
(5′–3′)
Length
(bp)
1a TCCAATCGGCGGAGTATATTAGAG AGAGGACGGCTGGGAGGGA 251
2Aa GCGCTGACCTACCTCCTTCCCT CACGATGCGGTTGCGGTC 313
2Bd GCTTCGGCTCAGGGTCCA CCAGGCGCGGGTGTGAG 132
3c GTACAATGTTCGTCTGTT GTCCACAGGAGCGATACT 100
4Aa CATGATTCACCACTTTGT GCATAGTGTCCAAAGAAG 190
4Ba CTGTAATAAGTTCTGCCG TCCCACCCCACCTGAGATA 195
5a GGAATTTGCAGACTTTAATGCAA CCTGCAGTCCCTGGGAGT 160
6d AAGGCTAACCTGGAGGTGTGCTGC TCCCACCCTGGGTCTCATCC 198
7a GTCTCTTAGTGACTCCA GCTTATAGAATGGTTGGGA 270
8d CATCCCTCTCTGACTGCCATCC ACCTCTCCCCAACGTGGTATCTT 217
9a GGATCTAATTGTCAGATGGAT GTCACAGGGATGTTCTTA 190
10a TTCCAAGGTGGGGGAGAT TGGAAACAAAGTCACTCAC 195
11a CACCCAGCGTAATAACCTT CTAGTGTCGCACAAATCT 175
12d TGAAGCCCTGTGTTTGTGGAATAC GAAAAGTAAAGGGAAGCGGAGGAG 318
13c GTTTTACTCTGATCCCTC CAAGGGGCAGTGGTAGTAAGT 260
14d GAATGCCGCATCTGTGGGTG AGGCTGGGGAGCACTGGTC 166
15a AGGAGGGAGCCATGAAAACTGC CAACATGACCCATACATCCCAGAG 251
16a GCCTGTCGTGAATGGTCCTGGA CAAGGCCAACTACCACTT 190
17b GCTATCTCTGGGACCCTT CCACGTGGGGCATAAAGTT 200
18a CCTCCAGACTGTTTCTGGATA GCAAGTCCCCAAGGGTGTCA 250
19c GTTGAAGTCCTCACTATT GTGGATGAGTGCTGGCTT 105
20a GTGTGGTCTTTGCTTTCT CCAGACGGAGACAGTCCTT 130
21a CATCAGTCCCTAAACTTGAACTCCATT CGCTCACCCCAGAAGACCCAT 196
22a GCTCACCCGTCTCCACCTGT GAACTGCGGCAGCCATCATGT 160
23a ATGGCTGCCGCAGTTCA CAAGCAGACATCCACCAT 350
24a CTTACACGTGTGTGGGTTTCTC GCCATCGAATAATGAGGT 230
25Ad GCAGACACAGATTGTCGA CGCCTCTGAACTCTTACT 190
25Ba AGTAAACGTGATGGAAAC CCCTCGACCTGATGGCTTTA 200
26Aa TCTTGGAGAGTTAATTGGTTTTGTGC CCTTGATGGGGACCGTGTTG 250
26Ba GCTGAACCAGATCAAAAACCCCA TTGTCCAGTTTGGGTGTTTTGTCG 239
26Ca GCGTATACGCTGGTAGACAGAGAAGA GACAGTTTAAAGAACTACAAGCCCTCAGA 196
a PCR: 35 cycles of 30 s at 94C, 1 min at 50C, and 30 s at 72C.
b PCR: 35 cycles of 30 s at 94C, 1 min at 52C, and 30 s at 72C.
c PCR: 35 cycles of 30 s at 94C, 1 min at 55C, and 30 s at 72C.
d PCR: 35 cycles of 20 s at 94C, 20 s at 60C, and 20 s at 72C.
Sequence Analysis
All confirmed shifts detected by SSCP analysis were
subsequently sequenced on an ABI 377 sequencer in the
core facility at The Children’s Hospital of Philadelphia.
Results
Deletion Detection
Fifty-four unrelated patients with clinically diagnosed
AGS were screened with microsatellite markers spanning
an ∼1.5-mB region encompassing JAG1 to determine
whether larger deletions were present, resulting in loss
of an allele and causing haploinsufficiency for the JAG1
gene product. Forty-five patients were reported by
Krantz et al. (1997b); the remaining patients were
screened as part of this study. Three patients (6%) were
found to have deletions ranging 1.5–6.5 mB in size. One
of these patients had a cytogenetically detectable deletion
(Krantz et al. 1997b). A second patient had an appar-
ently balanced translocation, involving chromosomes 2
and 20, that segregated with the disease phenotype in
her family and was subsequently found to have a mo-
lecularly detectable deletion within chromosome 20p12
(Spinner et al. 1994; Krantz et al. 1997b). The karyotype
of the third patient was normal at a resolution of 550
bands, with a deletion detected by molecular analysis
(Rand et al. 1995). All three patients’ deletions encom-
passed the entire JAG1 gene, resulting in haploinsuffi-
ciency for the gene product. The phenotypes of these
patients have been reported elsewhere (Spinner et al.
1994; Rand et al. 1995; Krantz et al. 1997b) and did
not show any difference from those of patients with
point mutations in the gene.
Mutation Detection
The 51 patients clinically diagnosed with AGS that
remained after screening for deletions of the entire gene
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Table 2
Summary of Mutations in JAG1 Identified in AGS Probands
Mutationa,b
Patient
Number
Parental Origin
of Mutationc Exon Protein Region
Effect on Protein
Structure
Deletion:
2692delTG 4 Paternal 18 EGF-like repeats Truncates protein
2531del4 6 De novo 17 EGF-like repeats Truncates protein
2531delCA 8 De novo 17 EGF-like repeats Truncates protein
2504del5 21 ND 16 EGF-like repeats Truncates protein
1104delAG 23 Maternal 4B DSL Truncates protein
2535del4 24 Maternal 17 EGF-like repeats Truncates protein
2066delC 29 Paternal 13 EGF-like repeats Truncates protein
1874delCA 32 ND 12 EGF-like repeats Truncates protein
3019delTG 36 De novo 22 CR region Truncates protein
3052delGT 60 Maternal 22 CR region Truncates protein
2504del5 65 De novo 16 EGF-like repeats Truncates protein
Insertion:
3102ins5 10 Paternal 23 CR region Truncates protein
2472insT 17 ND 16 EGF-like repeats Truncates protein
684insG 19 Maternal 2A 5′ of DSL Truncates protein
2587insG 20 ND 17 EGF-like repeats Truncates protein
1708ins4 47 De novo 10 EGF-like repeats Truncates protein
1618insC 50 ND 9 EGF-like repeats Truncates protein
2271insG 62 ND 14 EGF-like repeats Truncates protein
1618insC 66 ND 9 EGF-like repeats Truncates protein
Missense:
R184C 15 De novo 4A 5′ of DSL ?
R184H 56 ND 4A 5′ of DSL ?
Nonsense:
R235X 28 ND 5 EGF-like repeats Truncates protein
K392X 30 ND 9 EGF-like repeats Truncates protein
C306X 31 ND 7 EGF-like repeats Truncates protein
R739X 39 De novo 18 EGF-like repeats Truncates protein
Q398X 41 ND 9 EGF-like repeats Truncates protein
R866X 46d De novo 22 CR region Truncates protein
C892X 52 ND 23 CR region Truncates protein
Q820X 57 De novo 21 EGF-like repeats Truncates protein
S888X 59 ND 22 CR region Truncates protein
Splice site:
13292TrG 13 De novo 6 Splice-donor site ?
1761r12TrG 25 Paternal 11 Splice-acceptor site ?
18081GrT 44 ND 10 Splice-donor site ?
28711GrT 63 ND 20 Splice-donor site ?
Complex:
1072GCArTG 55 ND 4B DSL Truncates protein
a Numbering is that of Li et al. 1996, GenBank accession number U73936.
b Mutation nomenclature is that of Beaudet et al. 1993.
c ND indicates that it was not possible to confirm the parental origin of the mutation.
d Patient 46 has a paternally inherited P/R866 polymorphism and a 3024CrT change leading to a
nonsense mutation.
were screened for mutations in JAG1 by SSCP analysis.
All band shifts identified after electrophoresis were
sequenced.
Mutations were identified in 35 (69%) of 51 patients
screened. With the exceptions of a 5-bp deletion in exon
16, seen in two unrelated patients, and a C insertion at
base 1618 of exon 9, in another two unrelated patients,
all mutations were unique (seen in only one family; table
2). Eleven (31%) of the 30 mutations were small dele-
tions: 1 of these involved a single base pair, 6 involved
two bp, 2 involved 4 bp, and the recurrent mutation
seen in two patients involved a 5-bp deletion. This re-
current deletion occurs at a site in the gene where a 5-
bp GAAAG repeat sequence exists, with one of the re-
peats deleted in both patients. All deletions led to frame-
shifts that resulted in downstream stop codons and trun-
cated protein products (table 2). Eight (23%) of the
mutations were insertions. Of these, six were sin-
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Table 3
Polymorphisms Identified in JAG1 in AGS Probands
Polymorphisma Codon Change
Amino
Acid(s) Exon
1001C/T TGCrTGT Cys 4A
1991C/T ATCrATT Ile 13
2627A/C ACArACC Thr 17
2795C/T AGCrAGT Ser 20
P/R866 CCArCGA ProrArg 22
3830C/T TACrTAT Tyr 26B
3941T/C TATrTAC Tyr 26B
a Numbering is according to Li et al. 1996, GenBank accession
number U73936.
gle–base-pair insertions (including the C insertion at
base 1618 of exon 9, seen in two unrelated patients),
one patient had a 4-bp insertion, and one patient had a
5-bp insertion. All led to frameshifts resulting in a pre-
maturely truncated protein product. A single patient
(3%) had a complex rearrangement that involved an
insertion and a deletion, leading to a frameshift and a
truncated protein product. Nine patients (26%) had sin-
gle–base-pair changes that led to immediate stop codons
(nonsense mutations).
Four patients had mutations predicted to lead to al-
terations in splicing. Patients 13, 44, and 63 had mu-
tations in the consensus splice donor sites of exons 6,
10, and 20, respectively. Patient 25 had a TrG mutation
12 bp from the splice donor site of exon 13. The mu-
tation segregated with the AGS phenotype in this family
(found in the proband, her affected father, and her af-
fected sister) and was not seen in over 100 ethnically
matched controls. Heteroduplex mobility analysis was
performed on cDNA from the three affected patients in
this family with presumed splice-site alterations, and, in
all cases, an electrophoretic band shift was identified that
was not seen in control samples, consistent with an al-
ternatively spliced RNA product (data not shown).
Two patients (6%) with missense mutations have been
identified. The two missense mutations occurred at the
same amino acid residue (184), in one case changing the
normal arginine to a cysteine, and in the second case
changing it to a histidine. With the exception of the two
missense mutations, all other mutations identified in this
screening presumably result in truncated proteins min-
imally missing the transmembrane and intracellular
domains.
Several polymorphisms in JAG1 were also identified
through this screening (table 3). With the exception of
the P/R866 change, none of the polymorphisms led to
an altered amino acid residue. All polymorphisms were
seen in unaffected family members as well as in control
samples. The proline-to-arginine change at position 866
(P/R866) was seen in proband 46 and her unaffected
father. In addition, the proband has a de novo 3024CrT
change in the same codon that results in a stop codon
(table 2). The putative P/R866 polymorphism was also
present in a homozygous state in the unaffected mother
of another patient.
In those patients where both parental samples were
available (18/35), 10 mutations (56%) arose de novo,
and 8 (44%) were inherited. Parental origin was ma-
ternal for four of the inherited mutations and paternal
for the other four. Of the three patients with complete
gene deletions, one patient inherited the deleted chro-
mosome from her mildly affected father (Spinner et al.
1994), with the other two deletions appearing de novo.
In all cases, parents with JAG1 mutations had clinical
features consistent with a diagnosis of AGS or of an
AGS microform (having some of the physical findings
of AGS, but not enough to fit the criteria to establish a
full clinical diagnosis of AGS as set forth by Alagille et
al. 1987).
Genotype-Phenotype Correlation
To evaluate the functional significance of the muta-
tions identified in JAG1, we undertook a careful eval-
uation of phenotypes of patients with intragenic muta-
tions and of patients with larger deletions encompassing
the entire gene. Patients were evaluated for severity of
disease as defined by morbidity (heart surgery, liver
transplant) and mortality, as well as by the number of
clinical features met in establishing the diagnosis of AGS.
Although the number of patients with deletion of the
entire gene was small, there was no appreciable differ-
ence noted in the phenotypes of these patients (fig. 2).
This is in keeping with an earlier study that looked at
a greater number of patients with deletions reported in
the literature, prior to the identification of JAG1 as the
AGS disease gene (Krantz et al. 1997b). There was no
difference in severity or phenotypes among patients with
identified mutations and those in whom no mutations
in JAG1 have been found. No significant differences
were appreciated in phenotypes based on type (missense
vs. truncating) or localization of mutations. No renal
manifestations were seen in the two patients with mis-
sense mutations or in patients with disruption of the
JAG1 protein distal to the EGF-like repeats; however,
the numbers of patients are small, and the results are
not significant.
Discussion
In our analysis of 54 patients meeting the clinical cri-
teria for AGS, we were able to identify 3 patients (6%)
with deletions encompassing the entire JAG1 gene and
35 patients (65%) with intragenic mutations. Using the
techniques outlined in this article, we were able to iden-
tify a total of 38 (70%) of 54 unrelated AGS patients
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Figure 2 Phenotype-genotype correlations in AGS patients with identifiable mutations in JAG1. The JAG1 protein is depicted on the left
(SP, signal peptide; DSL, delta-serrate-lin12 conserved region; TM, transmembrane region). Localization of identified mutations is indicated by
the lines connecting the patient number to the protein diagram. A plus sign () indicates presence of feature, a minus sign () indicates absence
of feature, and a question mark (?) indicates unknown. Severity scale: (1)  subclinically affected; (2)  clinically affected, mild; (3) clinically
affected, severe (requiring surgical intervention or transplant), (4)  deceased.
with alterations in JAG1. All of the identified mutations
were unique, with the exceptions of patients 50 and 66,
who had a C insertion at base 1618 of exon 9, and
patients 21 and 65, who had the same 5-bp deletion in
exon 16. A 5-bp GAAAG repeat exists at this site in
exon 16, with both patients having deletions of one of
these repeats. The existence of this small repeated se-
quence may predispose it to recombination errors and
may account for the recurrent deletion seen in these two
unrelated patients.
With the exception of the two missense mutations, all
other mutations identified in this study are predicted to
result in a truncated protein. In all cases, these mutations
are predicted to lead to the deletion of at least the trans-
membrane and intracellular domains. The truncating
mutations all occur within the protein motifs that show
interspecies conservation and are thought to be impor-
tant in ligand-receptor interaction (Lindsell et al. 1995;
fig. 1). This report describes the first missense mutations
identified in JAG1. The two missense mutations occur
in the same amino acid residue (an arginine) at position
184. This position is upstream of the truncating muta-
tions that are spread throughout the DSL, EGF-like re-
peats, and CR region (fig. 3). No mutational hot spots
were found.
The identification of only two missense mutations
among the 38 changes identified is of interest. Several
other single–base-pair substitutions, leading to imme-
diate stop codons or resulting in polymorphisms that
either did not change the coded amino acid or led to a
conservative amino acid change, were identified (table
3). Since all of the truncating mutations identified in
JAG1 are predicted to result in proteins missing the se-
quence necessary to anchor them to the cell membrane,
we hypothesize that a mechanism for the expression of
the AGS phenotype is that of haploinsufficiency for the
JAG1 protein product. In Drosophila, mutant delta and
serrate (Notch ligands that are highly homologous to
JAG1) have been studied. These mutant proteins are
similar to the proteins we predict in some AGS patients
on the basis of our mutation analysis (i.e., truncated
proteins lacking the transmembrane and intracellular
domains). Studies in Drosophila have shown that these
mutant proteins are secreted and appear to have a dom-
inant negative effect on Notch signaling (Sun and Ar-
tavanis-Tsakonas 1996). Although we do not have direct
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Figure 3 Amino acid sequence of the 5′ end of the JAG1 protein,
up to and including the DSL domain (indicated by shaded box). Amino
acid 184 (arginine), the amino acid residue involved in the only two
missense mutations identified, to date, in JAG1, is denoted by a black-
ened box and demonstrates conservation from Drosophila to humans.
evidence that this is not occurring in some of our pa-
tients, we have shown that those patients with deletions
of the entire JAG1 gene display the same phenotype as
those with intragenic mutations leading to a truncated
protein. In addition, at least three of our patients with
intragenic alterations of JAG1 ( patients 19, 23, and 55)
have mutations that would severely truncate the protein
product, leading to loss of the domains that interact with
the Notch receptor. These findings are consistent with
haploinsufficiency for JAG1 causing AGS.
The two missense mutations in JAG1 at amino acid
residue 184 (arginine) are the only point mutations iden-
tified that do not result in a truncated protein product.
Arginine 184 lies two amino acids upstream of the DSL
domain and other conserved structures thought to be
involved in ligand-receptor interactions. This residue
shows high interspecies conservation (fig. 3) and may be
important in these interactions, either directly or through
its effect on secondary or tertiary protein structure.
These mutations may result in haploinsufficiency but
more likely result in an ineffective JAG1 protein and
may in fact have a dominant negative effect. Further
studies in lower organisms and in in vitro cellular sys-
tems will have to be undertaken to fully understand the
role these mutations play in the pathogenesis of AGS.
We were able to identify mutations in 38/54 patients
(70%) who met the diagnostic criteria for AGS, leaving
30% of patients with no detectable alteration in JAG1.
Explanations that could account for this include the in-
ability of the screening technique to detect all mutations,
or, alternatively, there may be another locus responsible
for AGS. SSCP has been shown to detect ∼80% of mu-
tations within coding regions and exon/intron bound-
aries (Orita et al. 1989). Partial gene deletions that in-
clude complete exons, conserving the remaining exons
and exon-intron boundaries, would potentially not be
detected by SSCP analysis. Alterations in the intronic
sequences that were not screened may lead to new splic-
ing events that could disrupt the protein as well. Protein
truncation and heteroduplex mobility-analysis assays
may be able to detect some of these types of changes.
Alterations in 5′ upstream sequences as well as 3′ down-
stream sequences involved in regulation of transcription
and processing would also not be detected by the present
methodology. Although no data have suggested another
locus responsible for AGS, the data mapping AGS to
20p12 are based on reports of patients with cytogenet-
ically detectable deletions of this region (Byrne et al.
1986; Schnittger et al. 1989; Anad et al. 1990; Leguis
et al. 1990; Zhang et al. 1990; Teebi et al. 1992; Spinner
et al. 1994; Rand et al. 1995; Krantz et al. 1997b) and
one isolated linkage study in a large three-generation
family (Hol et al. 1995). The Notch signaling pathway,
of which JAG1 is a component, has at least seven other
members identified in humans (Artavanis-Tsakonas et
al. 1995; Ellisen et al. 1991; Joutel et al. 1996; Li et al.
1997; Oda et al. 1997) and at least twice that many
identified in lower organisms (Muskavitch 1994; Arta-
vanis-Tsakonas et al. 1995). It is possible that mutations
in one or several of these other components or in still
other unidentified genes could also result in the AGS
phenotype.
The ability to provide molecular confirmation for AGS
will be of great benefit to families with an affected child.
The expression of AGS is extremely variable both be-
tween and within families. A molecular assay will permit
identification of family members with microforms of this
disorder, greatly improving our ability to appropriately
counsel affected families. Mutation identification in
JAG1 in any given AGS family will also allow for the
possibility of prenatal diagnosis.
Screening for mutations in JAG1 by SSCP analysis is
a daunting task because of the presence of almost ex-
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clusively private mutations across a large coding region.
Since the majority of mutations detected to date lead to
a prematurely terminated protein, the use of the protein-
truncation test (Roest et al. 1993; Becker et al. 1996)
may result in a simpler diagnostic assay.
Acknowledgments
As always, we are grateful for the support of the families
of the AGS patients we have studied. We are grateful to Dr.
Rebecca Oakey for helpful discussions, as well as to the nu-
merous clinicians who have submitted samples for analysis,
including Drs. B. Blumberg, B. Crandall, L. Pasztor, M.E. Pier-
pont, E. Spence, P. Whitington, M. Bialer, M. Bocian, J. Kabori,
M. Golabi, T. Costa, J. Graham, M. Jones, S. Bhatt, and G.
Kupchik, and genetic counselors K. Armfield, M. Fox, J. Der-
stine, C. Brasington, and M. Huggins. This work was sup-
ported by Clinical Research Grant FY-97-0565 from the
March of Dimes Birth Defects Foundation (to N.B.S.), and by
NIH grant 1R01DK53104-01 (to N.B.S.). This investigation
was also supported in part by Public Health Service (NIH)
research grant 3M01RR00240-32S7CRC (to I.D.K.), by the
McCabe Fund Pilot Project Award (to I.D.K.), by funds from
the “Newell DeValpine Foundation” (to E.B.R.), and by NIH
grant DK02338 (to E.B.R.).
Electronic-Database Information
Accession numbers and URLs for data in this article are as
follows:
GenBank, http://www.ncbi.nlm.nih.gov/Web/Genbank (for Al-
agille syndrome gene, Jagged1 [U73936])
Online Mendelian inheritance in man (OMIM), http://
www.ncbi.nlm.nih.gov/htbin-post/Omim (for Alagille syn-
drome [MIM 118450])
References
Alagille D, Estrada A, Hadchouel M, Gautier M, Odievre M,
Dommergues JP (1987) Syndromic paucity of interlobular
bile ducts. J Pediatr 110:195–200
Alagille D, Odievre M, Gautier M, Dommergues JP (1975)
Hepatic ductular hypoplasia associated with characteristic
facies, vertebral malformations, retarded physical, mental,
and sexual development, and cardiac murmur. J Pediatr 86:
63–71
Anad F, Burn J, Matthews D, Cross I, Davison BCC, Mueller
R, Sands M, et al (1990) Alagille syndrome and deletion of
20p. J Med Genet 27:729–737
Artavanis-Tsakonas S, Matsuno K, Fortini ME (1995) Notch
signaling. Science 268:225–232
Beaudet AL, Tsui LC (1993) A suggested nomenclature for
designating mutations. Hum Mutat 2:245-248
Becker K-F (1996) Nonradioactive protein truncation test
(nrPTT) for rapid detection of gene mutations. Trends Genet
12:250
Byrne JLB, Harrod MJE, Friedman JM, Howard-Peebles PN
(1986) Del(20p) with manifestations of arteriohepatic dys-
plasia. Am J Med Genet 24:673–678
Danks DM, Campbell PE, Jack I, Rogers J, Smith AL (1977)
Studies of the aetiology of neonatal hepatitis and biliary
atresia. Arch Dis Child 52:360–367
Dhorne-Pollet S, Deleuze J-F, Hadchouel M, Bonaiti-Pellie C
(1994) Segregation analysis of Alagille syndrome. J Med
Genet 31:453–457
Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith
SD, Sklar J (1991) TAN-1, the human homolog of the Dro-
sophila Notch gene, is broken by chromosomal transloca-
tions in T lymphoblastic neoplasms. Cell 66:649–661
Elmslie FV, Vivian AJ, Gardiner H, Hall C, Mowat AP, Winter
RM (1995) Alagille syndrome: family studies. J Med Genet
32:264–268
Hol FA, Hamel BCJ, Geurds MPA, Hansmann I, Nabben FAE,
Daniels O, Mariman ECM (1995) Localization of Alagille
syndrome to 20p11.2-p12 by linkage analysis of a three-
generation family. Hum Genet 95:687–690
Joutel A, Corpechot C, Docros A, Vahedi K, Chabriat H, Mou-
ton P, Alamowitch S, et al (1996) Notch3 mutations in
CADASIL, a hereditary adult-onset condition causing stroke
and dementia. Nature 383:707–710
Kopan R, Weintraub H (1993) Mouse Notch: expression in
hair follicles correlates with cell fate determination. J Cell
Biol 121:631–641
Krantz ID, Piccoli DA, Spinner NB (1997a) Syndrome of the
month: Alagille syndrome. J Med Genet 34:152–157
Krantz ID, Rand EB, Genin A, Hunt P, Jones M, Louis AA,
Graham JM, et al (1997b) Deletions of 20p12 in Alagille
syndrome: frequency and molecular characterization. Am J
Med Genet 70:80–86
Legius E, Fryns F-P, Eyskens B, Eggermont E, Desmet V, de
Bethune G, Van den Berghe H (1990) Alagille syndrome
(arteriohepatic dysplasia) and del(20)(p11.2). Am J Med Ge-
net 35:532–535
Li L, Krantz ID, Yu D, Genin A, Banta AB, Collins CC, Ming
Q, et al (1997) Alagille syndrome is caused by mutations in
human Jagged1, which encodes a ligand for Notch1. Nat
Genet 16:243–250
Lindsell CE, Shawber CJ, Boulter J, Weinmaster G (1995) Jag-
ged: a mammalian ligand that activates Notch1. Cell 80:
909–917
Muskavitch MAT (1994) Delta-Notch signaling and Dro-
sophila cell fate choice. Dev Biol 166:415–430
Oda T, Elkahloun AG, Pike BL, Okajima K, Krantz ID, Genin
A, Piccoli DA, et al (1997) Mutations in the human Jagged1
gene are responsible for Alagille syndrome. Nat Genet 16:
235–242
Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T
(1989) Detection of polymorphisms of human DNA by gel
electrophoresis as single-strand conformation polymor-
phisms. Proc Natl Acad Sci USA 86:2766–2770
Rand EB, Spinner NB, Piccoli DA, Whitington PF, Taub R
(1995) Molecular analysis of 24 Alagille syndrome families
identifies a single submicroscopic deletion and further lo-
Krantz et al.: Jagged1 Mutations in Alagille Syndrome 1369
calizes the Alagille region within 20p12. Am J Hum Genet
57:1068–1073
Robey E, Chang D, Itano A, Cado D, Alexander H, Lans D,
Weinmaster G, et al (1996) An activated form of Notch
influences the choice between CD4 and CD8 T cell lineages.
Cell 87:483–492
Roest PAM, Roberts RG, Sugino S, van Ommen GJB, den
Dunnen JT (1993) Protein truncation test (PTT) for rapid
detection of translation-terminating mutations. Hum Mol
Genet 2:1719–1721
Schnittger S, Hofers C, Heidemann P, Beermann F, Hansmann
I (1989) Molecular and cytogenetic analysis of an interstitial
20p deletion associated with syndromic intrahepatic duc-
tular hypoplasia (Alagille syndrome). Hum Genet 83:
239–244
Shulman SA, Hyams JS, Gunta R, Greenstein RM, Cassidy SB
(1984) Arteriohepatic dysplasia (Alagille syndrome): ex-
treme variability among affected family members. Am J Med
Genet 19:325–332
Spinner NB, Rand EB, Fortina P, Genin A, Taub R, Semeraro
A, Piccoli DA (1994) Cytologically balanced t(2;20) in a
two-generation family with Alagille syndrome: cytogenetic
and molecular studies. Am J Hum Genet 55:238–243
Sun X, Artavanis-Tsakonas S (1996) The intracellular deletions
of DELTA and SERRATE define dominant negative forms
of the Drosophila Notch ligands. Development 122:
2465–2474
Teebi AS, Murthy DSK, Ismail EAR, Redha AA (1992) Alagille
syndrome with de novo del(20) (p11.2). Am J Med Genet
42:35–38
Zhang F, Deleuze J-F, Aurias A, Dutrillaux A-M, Hugon R-
N, Alagille D, Thomas G, et al (1990) Interstitial deletion
of the short arm of chromosome 20 in arteriohepatic dys-
plasia (Alagille syndrome). J Pediatr 116:73–77
